Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab and Tislelizumab Plus Radiotherapy for Recurrent/Metastatic Cervical Cancer
NCT06039891Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab and tislelizumab in Cervical Cancer (CC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-free survival at 1 year. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
nimotuzumabtislelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06039891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06039891.